An observational study in Open-angle Glaucoma and Ocular Hypertension, sponsored by Allergan. Completed at 39 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-03.
Study to collect effectiveness and safety data after administration of a bimatoprost intracameral implant in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
924 studies on the registry are indexed under Glaucoma, Open-Angle; 117 are open to participants now.
This study's enrollment of 220 is above the median of 101 across 184 observational studies indexed under Glaucoma, Open-Angle.
Browse Glaucoma, Open-Angle studies →Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
First submitted after Allergan became part of AbbVie.
Counted across the registry records on this site, refreshed daily.
The study population will include US patients with OAG or OHT who are scheduled for administration of a bimatoprost intracameral implant by their ophthalmologist.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Patient diagnosed with OAG or OHT who is scheduled to receive a bimatoprost intracameral implant in at least one eye.
Exclusion Criteria:
- A history of any of the following ocular surgeries in the eye due to receive a bimatoprost intracameral implant:Ahmed Glaucoma Valve, Baerveldt shunt, Ex-Press glaucoma shunt implantation, Molteno shunt, Trabeculectomy, Vitrectomy, retinal surgery, CyPass Micro-Stent or Anterior Chamber Intraocular Lens (AC IOL) placement.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with OAG or OHT who are scheduled for intracameral administration of a bimatoprost intracameral implant by their ophthalmologist.
Proportion of treated eyes that did not receive additional Intraocular Pressure (IOP) -lowering intervention/therapy per standard medical care
IOP is a measurement of the fluid pressure inside the study eye. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.
Time frame: Baseline to Month 6
Proportion of treated eyes not receiving additional IOP-lowering intervention/therapy per standard medical care
IOP is a measurement of the fluid pressure inside the study eye. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.
Time frame: Baseline to Month 4
Proportion of treated eyes not receiving additional IOP-lowering intervention/therapy per standard medical care
IOP is a measurement of the fluid pressure inside the study eye. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.
Time frame: Baseline to Month 9
Proportion of treated eyes not receiving additional IOP-lowering intervention/therapy per standard medical care
IOP is a measurement of the fluid pressure inside the study eye. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.
Time frame: Baseline to Month 12
Proportion of treated eyes not receiving additional IOP-lowering intervention/therapy per standard medical care
IOP is a measurement of the fluid pressure inside the study eye. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.
Time frame: Baseline to Month 18
Time from bimatoprost intracameral implant to first additional IOP-lowering intervention/therapy
Time to first IOP-lowering intervention is defined as the time between treatment and IOP-lowering intervention.
Time frame: Baseline to Month 18
Proportion of treated eyes achieving the predefined IOP outcomes without receiving additional IOP-lowering intervention/therapy
IOP is a measurement of the fluid pressure inside the study eye. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.
Time frame: Baseline to Month 4
Proportion of treated eyes achieving the predefined IOP outcomes without receiving additional IOP-lowering intervention/therapy
IOP is a measurement of the fluid pressure inside the study eye. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.
Time frame: Baseline to Month 6
Proportion of treated eyes achieving the predefined IOP outcomes without receiving additional IOP-lowering intervention/therapy
IOP is a measurement of the fluid pressure inside the study eye. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.
Time frame: Baseline to Month 9
Proportion of treated eyes achieving the predefined IOP outcomes without receiving additional IOP-lowering intervention/therapy
IOP is a measurement of the fluid pressure inside the study eye. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.
Time frame: Baseline to Month 12
Proportion of treated eyes achieving predefined IOP outcomes without receiving additional IOP-lowering intervention/therapy
IOP is a measurement of the fluid pressure inside the study eye. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.
Time frame: Baseline to Month 18
Mean reduction in the number of topical IOP-lowering medications
A numerical count by class of drug of topical IOP lowering medications being taken.
Time frame: Baseline to Month 4
Mean reduction in the number of topical IOP-lowering medications
A numerical count by class of drug of topical IOP lowering medications being taken.
Time frame: Baseline to Month 6
Mean reduction in the number of topical IOP-lowering medications
A numerical count by class of drug of topical IOP lowering medications being taken.
Time frame: Baseline to Month 9
Mean reduction in the number of topical IOP-lowering medications
A numerical count by class of drug of topical IOP lowering medications being taken.
Time frame: Baseline to Month 12
Mean reduction in the number of topical IOP-lowering medications
A numerical count by class of drug of topical IOP lowering medications being taken.
Time frame: Baseline to Month 18
Proportion of treated eyes achieving complete success
Complete success is defined as treated eyes with IOP \<=18 mm Hg without any additional IOP lowering interventions/therapies after administration of the bimatoprost intracameral implant.
Time frame: Baseline to Month 4
Proportion of treated eyes achieving complete success
Complete success is defined as treated eyes with IOP \<=18 mm Hg without any additional IOP lowering interventions/therapies after administration of the bimatoprost intracameral implant.
Time frame: Baseline to Month 6
Proportion of treated eyes achieving complete success
Complete success is defined as treated eyes with IOP \<=18 mm Hg without any additional IOP lowering interventions/therapies after administration of the bimatoprost intracameral implant.
Time frame: Baseline to Month 9
Proportion of treated eyes achieving complete success
Complete success is defined as treated eyes with IOP \<=18 mm Hg without any additional IOP lowering interventions/therapies after administration of the bimatoprost intracameral implant.
Time frame: Baseline to Month 12
Proportion of treated eyes achieving complete success
Complete success is defined as treated eyes with IOP \<=18 mm Hg without any additional IOP lowering interventions/therapies after administration of the bimatoprost intracameral implant.
Time frame: Baseline to Month 18
Proportion of treated eyes achieving qualified success
Partial success is defined as treated eyes with IOP \<=18 mm Hg with no Secondary Surgical Intervention (SSI) for glaucoma, while staying on the same or fewer topical IOP-lowering medications than baseline and or Selective Laser Trabeculoplasty (SLT), Argon Laser Trabeculoplasty (ALT) or MicroPulse Laser Trabeculoplasty (MLT).
Time frame: Baseline to Month 4
Proportion of treated eyes achieving qualified success
Partial success is defined as treated eyes with IOP \<=18 mm Hg with no Secondary Surgical Intervention (SSI) for glaucoma, while staying on the same or fewer topical IOP-lowering medications than baseline and or Selective Laser Trabeculoplasty (SLT), Argon Laser Trabeculoplasty (ALT) or MicroPulse Laser Trabeculoplasty (MLT).
Time frame: Baseline to Month 6
Proportion of treated eyes achieving qualified success
Partial success is defined as treated eyes with IOP \<=18 mm Hg with no Secondary Surgical Intervention (SSI) for glaucoma, while staying on the same or fewer topical IOP-lowering medications than baseline and or Selective Laser Trabeculoplasty (SLT), Argon Laser Trabeculoplasty (ALT) or MicroPulse Laser Trabeculoplasty (MLT).
Time frame: Baseline to Month 9
Proportion of treated eyes achieving qualified success
Partial success is defined as treated eyes with IOP \<=18 mm Hg with no Secondary Surgical Intervention (SSI) for glaucoma, while staying on the same or fewer topical IOP-lowering medications than baseline and or Selective Laser Trabeculoplasty (SLT), Argon Laser Trabeculoplasty (ALT) or MicroPulse Laser Trabeculoplasty (MLT).
Time frame: Baseline to Month 12
Proportion of treated eyes achieving qualified success
Partial success is defined as treated eyes with IOP ≤18 mm Hg with no Secondary Surgical Intervention (SSI) for glaucoma, while staying on the same or fewer topical IOP-lowering medications than baseline and or Selective Laser Trabeculoplasty (SLT), Argon Laser Trabeculoplasty (ALT) or MicroPulse Laser Trabeculoplasty (MLT).
Time frame: Baseline to Month 18
Number of participants experiencing treatment emergent adverse events
Time frame: Baseline to Month 18
Plan to share: Undecided
Ran from Mar 2021 to primary completion in Jul 2024, 40 months.
Of 53 observational studies under Glaucoma, Open-Angle, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12. This study's 40 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.